| 000 | 01589 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250516013849.0 | ||
| 264 | 0 | _c20110411 | |
| 008 | 201104s 0 0 eng d | ||
| 022 | _a1083-351X | ||
| 024 | 7 |
_a10.1074/jbc.M110.168955 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGarcia-Perez, Javier | |
| 245 | 0 | 0 |
_aNew insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection. _h[electronic resource] |
| 260 |
_bThe Journal of biological chemistry _cFeb 2011 |
||
| 300 |
_a4978-90 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAllosteric Regulation _xdrug effects |
| 650 | 0 | 4 |
_aChemokine CCL3 _xmetabolism |
| 650 | 0 | 4 |
_aCyclohexanes _xpharmacology |
| 650 | 0 | 4 |
_aGuanosine Triphosphate _xanalogs & derivatives |
| 650 | 0 | 4 | _aHEK293 Cells |
| 650 | 0 | 4 |
_aHIV Envelope Protein gp120 _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 |
_aHIV-1 _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLigands |
| 650 | 0 | 4 | _aMaraviroc |
| 650 | 0 | 4 |
_aProtein Binding _xdrug effects |
| 650 | 0 | 4 |
_aReceptors, CCR5 _xagonists |
| 650 | 0 | 4 |
_aTriazoles _xpharmacology |
| 700 | 1 | _aRueda, Patricia | |
| 700 | 1 | _aStaropoli, Isabelle | |
| 700 | 1 | _aKellenberger, Esther | |
| 700 | 1 | _aAlcami, Jose | |
| 700 | 1 | _aArenzana-Seisdedos, Fernando | |
| 700 | 1 | _aLagane, Bernard | |
| 773 | 0 |
_tThe Journal of biological chemistry _gvol. 286 _gno. 7 _gp. 4978-90 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1074/jbc.M110.168955 _zAvailable from publisher's website |
| 999 |
_c20411040 _d20411040 |
||